Impact of overall treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemo-radiation and image-guided adaptive.

Slides:



Advertisements
Similar presentations
In the name of God Isfahan medical school Shahnaz Aram MD.
Advertisements

Incorporating Cesium-131 Interstitial Implants into Daily Clinical Practice: How to Make Radiation appear exactly where you want. Jonathan Feddock, MD.
Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD.
Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.
Casulo C et al. Proc ASH 2013;Abstract 510.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
V. Budach – Statements on H&N Cancer - 1 Discussion Panel on Primary Radiochemotherapy Volker Budach, MD, PhD Head Department for Radiation Oncology Charité.
Cervical Cancer Case Study Eshetu Atenafu, Sandra Gardner, So-hee Kang, Anjela Tzontcheva University of Toronto Department of Public Health Sciences (Biostatistics)
IMRT vs. BRACHYTHERAPY FOR SOFT TISSUE SARCOMA. EXTERNAL RT IN STS NCI Trial (Yang JC et al, JCO 1998) Extremity / Superficial Trunk STS (n=141) LSS Alone.
Impact of imaging on newer radiation techniques in Gynaecological cancer.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Hot topics in breast radiotherapy Mark Beresford.
Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
Prevention by intravesical hyaluronic acid (Cystistat®) of acute radiation-induced cystitis in radiotherapeutic management of cervical cancer E. González.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
Clinical Outcomes and Patterns of Failure in Pineoblastoma: A 30-year Single Institution Experience Benjamin Farnia, B.A. ASTRO Poster Discussion September.
Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;
Endometrial Carcinoma
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.
Post-Resection CA 19-9 Predicts Overall Survival in Patients Treated with Adjuvant Chemoradiation; RTOG 9704 A. Berger, K. Winter, J. Hoffman, W. Regine,
Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.
Prospective Phase I/II Trial of Carbon Ion Radiotherapy for Locally Advanced Non-small-cell Lung Cancer (NSCLC) Abstract title: CIRT for Locally Advanced.
Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.
Multicenter Study of Down-staging of Hepatocellular Carcinoma (HCC) to within Milan Criteria before Liver Transplantation Neil Mehta, MD; Jennifer Guy,
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Title: Stereotactic Ablative Radiotherapy (SABR) can be Safe and Effective for Treatment of Central and Ultra-Central Lung Tumors. Author: Aadel Chaudhuri,
Long-Term versus Short-Term Androgen Deprivation Combined with High-Dose Radiotherapy for Intermediate and High Risk Prostate Cancer: Preliminary Results.
Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial Authors: Oliver et al,
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.
Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.
Jin MENG Shen FU (DPD 08) Biology 2 - Head/Neck and CNS Tumors
Tumor Location Correlates with Radiation Pneumonitis after Stereotactic Body Radiation Therapy (SBRT) for Primary and Oligometastatic Lesions of the Lung.
Poster # 18, abstract # 4530 Long term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous.
Outcome of patients treated with Image Guided Brachytherapy for Locally Advanced Carcinoma of the Cervix at Royal Devon & Exeter Hospital Dr.
Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,
M ETHODS Median dose was 22Gy (range: ) in 1 to 5 fractions Median treatment volume was 12.6 cc (range: ). Assessed for eligibility.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Increased Local Control of Lung and Liver Tumors Associated with Dose-Escalated Stereotactic Body Radiation Therapy (SBRT) Supports a Dose-Response Relationship.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.
SARC018: A SARC PILOT MULTICENTER STUDY OF PREOPERATIVE RADIATION AND SURGERY IN PATIENTS WITH HIGH- RISK DESMOID TUMORS Robert S. Benjamin, M.D.
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
Patient and Tumour Characteristics Median age 60 years (26-92) Karnofsky Status:median 90 (50-100) Histology:SCC: n=120 (83%) Tumor size: ≥ 5 cm: n=78.
Is it possible to predict New Onset Diabetes After Transplantation (NODAT) in renal recipients using epidemiological data alone? Background NODAT is an.
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.
The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.
Image Guided Interstitial Brachytherapy For Locally Advanced Gynaecological Cancer With A MUPIT Applicator M.A.D. Haverkort, MD 1, E. Van der Steen - Banasik,
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Signs, Symptoms, Interventions ACKNOWLEDGEMENTS AND CONTACTS
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Brain imaging prior to lung cancer resection
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Relationship between the site of esophageal carcinoma and survival of patients with locally advanced disease Authors: Andrea Masarykova, Ingrid Zavacka,
Dose-escalation patient response.
Coiffier B et al. Proc ASH 2010;Abstract 857.
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies  Richard Pötter,
Untch M et al. Proc SABCS 2010;Abstract P
Cone beam computed tomography-based monitoring and management of target and organ motion during external beam radiotherapy in cervical cancer  Nina Boje.
Charles R. Nolan, Wajeh Y. Qunibi  Kidney International 
Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.
Presentation transcript:

Impact of overall treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemo-radiation and image-guided adaptive brachytherapy Renaud Mazeron # (abstract 1827) DPD 06. Digital Poster Discussion - GYN

GUSTAVE ROUSSYMazeron R ASTRO GYN PD6 Background Image-guided adaptive brachytherapy (IGABT) is becoming a standard in the treatment of locally advanced cervical cancer Local control rates reported in monocentric series are high, about 90% (Pötter et al., Nomden et al., Mazeron et al.) Objective: Identifying the prognosis factors for local control in a cohort a patients treated with concomitant chemo-radiation followed by IGABT 2

GUSTAVE ROUSSYMazeron R ASTRO GYN PD6 Material and Methods Consecutive patients Locally advanced cervical cancer (IB2-IVA) Curative intent GEC-ESTRO recommendations applied At the beginning of our experience, patients with stage I-II lesions went throughout post radiation hysterectomy. For them, local failure was considered in case of macroscopic remnant (1 cm in width) or in case of local relapse during their follow-up. In patients treated with definitive radiotherapy, local failure was defined as any relapse in the cervix, vagina, parametium, or uterus during the follow-up. 3

GUSTAVE ROUSSYMazeron R ASTRO GYN PD6 Note: Post radiation hysterectomy Patients included to warrant consecutive patients Treated at the beginning of our experience, with doses lower than nowadays. Important to study dose- response effect. 1cm as cutoff: strong prognosis factor reported in the literature Prognostic factors were analyzed using a linear regression model. Additional dose / effect correlations were done using the logit model. 4 Statistics

GUSTAVE ROUSSYMazeron R ASTRO GYN PD6 Results Tumor width at diagnosis (> 5 cm), initial tumor volume (>50 cm 3 ), D90% of the HR-CTV (high risk, > 85 Gy), the HR-CTV volume (> 30 cm 3 ) and overall treatment time (OTT, > 55days) appeared significantly correlated with local control in univariate analysis, but treatment duration remained the only significant factor in multivariate analysis (p=0.022, odds ratio=2.44). Logit models: positive for OTT, D90 HR and IR-CTV 5

GUSTAVE ROUSSYMazeron R ASTRO GYN PD6 Figure 1 6

GUSTAVE ROUSSYMazeron R ASTRO GYN PD6 7

GUSTAVE ROUSSYMazeron R ASTRO GYN PD6 Take home messages OTT remains important with a loss of 0,5% of local control probability beyond 55 days This is less than reported 10 years ago (1%) but significant A dose-response for both HR-IR CTV has been shown similar to that demonstrated by Dimopoulos et al. for HDR brachytherapy, supporting the dose escalation concept (see oral presentation by Kari Tanderup) 8

If any query, please contact me: Radiation therapy department